Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the ...

Q1 2025 Earnings Call Transcript May 12, 2025 Relmada Therapeutics, Inc. misses on earnings expectations. Reported EPS is $-0 ...

Welcome to the Relmada Therapeutics first-quarter 2025 earnings call. (Operator Instructions) As a reminder, this conference is being recorded, and will be available for replay on the location website ...

Positive initial Phase 2 proof-of-concept data for NDV-01 at AUA 2025 showing a 90% overall response rate at any time in non-muscle invasive bladder cancer (US prevalence 600K patients) The Phase 2 st ...

The 17-year-old girl was diagnosed with a neuro attack, which landed her on a wheelchair, but her grit and confidence to ...

ACADIA Pharmaceuticals has a rock solid balance sheet and advancing a couple of key drug candidates within its pipeline.

The results of an international study shed new light the underlying biological mechanisms which cause differences in health risks, symptoms and outcomes between males and females.

Research and Development (R&D) Expenses. R&D expenses were $25.3 million for the three-month period ended March 31, 2025, compared to $12.4 million for the three-month period ended March 31, 2024. The ...